Skip to main content
CIThe Cigna GroupSell6.0·$289.71+0.08%
Open full analysis

The Cigna Group (CI) Stock Analysis

Breakout setup

SellModerate Confidence

Healthcare · Healthcare Plans

Sell if holding. Engine safety override at $289.71: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10. Specifically: Below-average business quality.

Cigna Group is a global health company with two segments: Evernorth Health Services (pharmacy benefit management via Express Scripts, specialty pharmacy Accredo, and care services) and Cigna Healthcare (employer and individual health insurance, international health). Serves... Read more

$289.71+5.8% A.UpsideScore 6.0/10#1 of 11 Healthcare Plans
QualityF-score7 / 9FCF yield9.04%
IncomeYield2.15%(5y avg 1.68%)Payout5.36%sustainable
Stop $274.75Target $306.45(analyst − 10%)A.R:R 0.8:1
Analyst target$340.50+17.5%24 analysts
$306.45our TP
$289.71price
$340.50mean
$400

Sell if holding. Engine safety override at $289.71: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 54, MACD bullish. Score 6.0/10, moderate confidence.

Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.

10-K grounded · weekly refresh

About The Cigna Group

About The Cigna Group

The Cigna Group served more than 185 million customer relationships across more than 30 markets and jurisdictions as of December 31, 2025, through two segments: Evernorth Health Services (pharmacy benefit management, specialty pharmacy, and care services) and Cigna Healthcare (commercial medical plans and international health). On March 19, 2025, the company completed the sale of its Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plan, and supplemental benefits businesses to Health Care Service Corporation. Individual and family plan offerings are currently available in 11 states.

Evernorth Health Services — anchored by the Express Scripts pharmacy benefit brand and Accredo Specialty Pharmacy (35 licensed pharmacies) — earns fees from processing pharmacy benefit claims, managing drug formularies and rebates, and distributing specialty pharmaceuticals through CuraScript SD (four distribution centers). Three clients each drive significant Evernorth revenues: Centene Corporation under a multiyear agreement from January 1, 2024; Prime Therapeutics; and TRICARE, the U.S. Department of Defense military health care program. Evernorth sources roughly half of pharmaceutical purchases from a single wholesaler, with backup contracts available from other wholesalers. Cigna Healthcare generates premiums and ASO fees from employer medical plans, individual and family plans, and international health coverage; ASO arrangements represented approximately 32% of 2025 Cigna Healthcare segment revenues, covering 79% of Cigna Healthcare medical customers. The 10 largest retail pharmacy chains represent approximately 47% of total stores in Cigna's largest pharmacy network.

Show full overview

Evernorth announced a rebate-free pharmacy benefit model that Cigna Healthcare's fully insured customers plan to adopt from 2027, with all Evernorth Health Services clients intending to transition to the new standard model from 2028. The Inflation Reduction Act granted CMS authority to negotiate prices for high-cost Medicare Part D and Part B drugs; the 10-K notes drug companies may adjust broader market pricing strategies in response, which could affect formulary rebate economics. If pharmaceutical manufacturers reduce rebates during the transition to the rebate-free model, pharmacy benefit segment margins could be affected, depending on how quickly the new model gains client adoption.

See also: Healthcare · Healthcare Plans

From The Cigna Group's most recent 10-K filing, extracted June 9, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-06-09

Recent Developments — The Cigna Group

Generated 2026-06-15T18:11:46Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Jul 30, 202651d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Supplier: one pharmaceutical wholesaler (approximately half of pharmaceutical purchases)
Cyclical trap - fwd PE 9x vs trail 3x (3.4x)
Quality below floor (3.9 < 4.0)

Key Metrics

P/E (TTM)2.5
P/E (Fwd)8.7
Mkt Cap$76.6B
EV/EBITDA7.5
Profit Mgn2.3%
ROE16.3%
Rev Growth4.6%
Beta0.30
Dividend2.15%
Rating analysts33

Quality Signals

Piotroski F7/9

Options Flow

P/C0.95neutral
IV41%normal
Max Pain$230-20.6% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHSupplierone pharmaceutical wholesaler (approximately half of pharmaceutical purchases)
    10-K Item 1: 'Evernorth Health Services uses one wholesaler for approximately half of our pharmaceutical purchases, but holds contracts with other wholesalers if needs for an alternate source arise'

Material Events(8-K, last 90d)

  • 2026-03-03Item 5.02MEDIUM
    Brian C. Evanko appointed CEO effective July 1, 2026, succeeding David M. Cordani who retires as CEO and becomes Executive Chair. Clean handoff with named successor; Cordani stays on as Executive Chair.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Gross Margin
0.0
Net Margin
1.1
Operating Margin
2.2
Roa
3.2
Current Ratio
3.3
Moat
5.0
Roe
5.4
Fcf Quality
7.5
Piotroski F
7.8
No competitive moatStrong Piotroski F-Score: 7/9
GatesA.R:R 0.8 < 1.5@spotExecutive change: officer departure/appointmentMomentum 7.2>=5.5Insider activity: OKNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 51d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARBreakoutSuitability: Moderate
RSI
54 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $268.87Resistance $301.58

Price Targets

$275
$306
A.Upside+5.8%
A.R:R0.8:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Cyclical trap - fwd PE 9x vs trail 3x (3.4x)
! Quality below floor (3.9 < 4.0)
! asymmetry at 0.8 (below the engine's 1.5 threshold)@spot

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-07-30 (51d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CI stock a buy right now?

Sell if holding. Engine safety override at $289.71: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10. Specifically: Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 54, MACD bullish. Prior stop was $274.75. Score 6.0/10, moderate confidence.

What is the CI stock price target?

Take-profit target: $306.45 (+5.8% upside). Prior stop was $274.75. Stop-loss: $274.75.

What are the risks of investing in CI?

Concentration risk — Supplier: one pharmaceutical wholesaler (approximately half of pharmaceutical purchases); Cyclical trap - fwd PE 9x vs trail 3x (3.4x); Quality below floor (3.9 < 4.0).

Is CI overvalued or undervalued?

The Cigna Group trades at a P/E of 2.5 (forward 8.7). TrendMatrix value score: 8.3/10. Verdict: Sell.

What do analysts say about CI?

33 analysts cover CI with a consensus score of 4.2/5. Average price target: $341.

What does The Cigna Group do?Cigna Group is a global health company with two segments: Evernorth Health Services (pharmacy benefit management via...

Cigna Group is a global health company with two segments: Evernorth Health Services (pharmacy benefit management via Express Scripts, specialty pharmacy Accredo, and care services) and Cigna Healthcare (employer and individual health insurance, international health). Serves 185M+ customer relationships in 30+ markets; revenue from pharmacy fees, health premiums, and ASO fees.

Related stocks: CVS (CVS Health Corporation) · CNC (Centene Corporation) · HUM (Humana Inc.) · ELV (Elevance Health, Inc.) · UNH (UnitedHealth Group Incorporated)
Home Stocks CI

Latest news

Latest News

Benzinga13d agoCONCERN
Benzinga7d ago
Benzinga20d ago
Benzinga24d ago
Benzinga24d agoAnalyst
Benzinga26d agoAnalyst
Benzinga26d ago
Benzinga26d ago
Benzinga33d agoEarnings
Benzinga41d ago
Benzinga42d agoAnalyst
Benzinga45d ago
Benzinga45d agoAnalyst
Benzinga45d agoAnalyst
Benzinga45d agoAnalyst
Benzinga46d ago
Benzinga46d agoEarnings
Benzinga46d agoEarnings
Benzinga47d agoEarnings
Benzinga47d ago
Loading more...